A randomized, placebo-controlled, double-blind, pilot study of cannabis-related driving impairment assessed by driving simulator and self-report.

Aims: In the context of increasing cannabis use, understanding how cannabis affects specific driving behaviors is crucial in mitigating risks and ensuring road safety.

Design And Setting: The current study included 38 adults aged 18-40 years, administered a single 0.5 g acute dose of vaporized cannabis (5.

Switching from menthol to non-menthol cigarettes does not impact acute responses to intravenous nicotine.

Background: Limited research exists on how switching from menthol to non-menthol cigarettes affects the acute response to nicotine for individuals who smoke menthol cigarettes. Such research can inform public health strategies to reduce smoking prevalence.

Aims: This study investigated whether switching from menthol to non-menthol cigarettes for two weeks alters the acute responses to intravenous nicotine infusions delivered at different rates.

"Ice" flavor elements in E-cigarette images: Influence on liking and intention to use among youth who are at risk of E-cigarette use.

Introduction: "Ice"-flavored e-liquids and e-cigarettes, marketed as both sweet and cooling recently entered the US marketplace and are popular among youth. Advertisements featuring attractive product images and descriptions are one of the first exposures to these products for youth. This study examines the appeal of e-cigarette images, with and without a cooling "ice" imagery, among youth who have limited e-cigarette use or who are at risk of future use.

Cognitive Behavioral Therapy and Lisdexamfetamine, Alone and Combined, for Binge-Eating Disorder With Obesity: A Randomized Controlled Trial.

Objective: Binge-eating disorder (BED) is a prevalent, costly public health problem associated with serious functional impairments and heightened rates of psychiatric and medical comorbidities. Few evidence-based treatments are currently available for BED. We tested the effectiveness of cognitive-behavioral therapy (CBT), lisdexamfetamine (LDX), and combined CBT+LDX, for BED comorbid with obesity.